Responses
Technology and guidelines
Emerging transcatheter therapies for aortic and mitral disease
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 23 November 2015
- Published on: 23 November 2015Cost effectiveness of transcatheter aortic valvesShow More
One issue that has not been discussed in the paper by Christofferson et al. [1] is the cost-effectiveness of transcatheter therapies, particularly those based on the new transcatheter aortic valves.
Previous cost-effectiveness studies on surgical aortic valve replacement (AVR) compared AVR versus best medical therapy (or no operation) and found that AVR had an acceptable cost-effectiveness profile (cost per qua...
Conflict of Interest:
None declared.